Richard S. Finn, MD

Richard S. Finn, MD, an assistant professor of clinical medicine at the Geffen School of Medicine at the University of California, Los Angeles (UCLA), and director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the real-world findings from the REFINE study, which is exploring the outcomes of patients with unresectable hepatocellular carcinoma (HCC) who received treatment with regorafenib (Stivarga) compared with those in the clinical setting who were treated on the phase 3 RESORCE study.

In the real-world findings, just more than half of the doctors start patients on the full dose as prescribed, while others started patients at 80 or 120 mg per day, Finn says. Regardless, the efficacy and side effect profiles were similar between those treated in the real world versus the clinical trial setting.

Finn says that in terms of the length of time patients received regorafenib, the findings were comparable at about 4 months. Dose reductions were fairly common, regardless of the dose.

When investigators looked at why doctors used a lower dose, there seemed to be a relation with their prior dose of sorafenib (Nexavar). In the RESORCE study, patients received a fixed dose of regorafenib, and there was no effect on the efficacy and tolerability of the drug. Patients who were on sorafenib for a shorter period of time, they still received a similar magnitude of benefit with regorafenib, and vice versa, Finn says.

Videos

Richard S. Finn, MD, discusses the real-world findings from the REFINE study of patients with unresectable hepatocellular carcinoma who received treatment with regorafenib.

Real-World Findings in REFINE Study Support Use of Regorafenib in HCC

Richard S. Finn, MD, professor of Clinical Medicine Division of Hematology/Oncology, UCLA David Geffen School of Medicine, University of California, Los Angeles, discusses the considerations he makes when selecting frontline treatment for patients with advanced hepatocellular carcinoma (HCC).

Both sorafenib (Nexavar) and lenvatinib (Lenvima) have been approved by the FDA for the treatment of patients with advanced HCC in the frontline setting. The REFLECT trial that compared the 2 agents was a noninferiority trial, so Finn says neither agent is superior to the other.

According to both traditional and modified RECIST criteria, lenvatinib has a higher response rate, but no drug has ever been able to beat the survival rates seen with sorafenib, Finn notes. Data from the REFLECT study showed that if a patient has a response with either agent, that could provide a survival of 22 months, or even more in select patient populations.

Richard S. Finn, MD, discusses the considerations he makes when selecting frontline treatment for patients with advanced hepatocellular carcinoma.

Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCC

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses&nbsp;advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer. &nbsp; &nbsp;

Latest Advances in the Development of CDK4/6 Inhibitors in HR+ Breast Cancer

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the role of immunotherapy in the treatment of liver cancer.

Richard S. Finn, MD | Authors

Articles

Real-World Findings in REFINE Study Support Use of Regorafenib in HCC

Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCC

Latest Advances in the Development of CDK4/6 Inhibitors in HR+ Breast Cancer

The Role of Immunotherapy in Liver Cancer